Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 12/20 | 1.00 |
| ▸ | ACHE | P22303 | 12/20 | 1.00 |
| ▸ | APP | P05067 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9747579 | 0.91 | BCHE (0.83) | BCHEACHEAPPMAPTNPC1 | |
| SCHEMBL10061970 | 0.86 | ACHE (0.74) | BCHEACHEAPPMAPT | |
| SCHEMBL10062368 | 0.82 | MAPT (0.74) | BCHEACHEAPPMAPTNPC1 | |
| SCHEMBL13253522 | 0.76 | BCHE (0.60) | BCHEACHEMAPT | |
| SCHEMBL10062380 | 0.75 | KDM5A (0.70) | BCHEACHEMAPT | |
| SCHEMBL10061973 | 0.75 | NQO2 (0.62) | BCHEACHEMAPT | |
| SCHEMBL10062375 | 0.74 | BCHE (0.58) | BCHEACHEMAPT | |
| SCHEMBL10061811 | 0.74 | MEN1 (0.69) | BCHEACHEAPPMAPTNPC1 | |
| SCHEMBL7941639 | 0.73 | ACHE (0.61) | BCHEACHEAPPMAPT | |
| SCHEMBL8476129 | 0.73 | HTT (0.73) | BCHEACHEMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304206-B2 | Mass spectrometry assays for identifying compounds that activate deacetylases | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-11-06 | — | — | US | disclosed |
| US-8304206-B2 | Mass spectrometry assays for identifying compounds that activate deacetylases | SIRTRIS PHARMACEUTICALS, INC. (US) | 2012-11-06 | — | — | US | disclosed |
| EP-1955077-B1 | MASS SPECTROMETRY ASSAYS FOR ACETYLTRANSFERASE/DEACETYLASE ACTIVITY | SIRTRIS PHARMACEUTICALS INC (US) | 2012-06-13 | — | — | EP | disclosed |
| EP-1853920-B1 | FLUORESCENCE POLARIZATION ASSAYS FOR ACETYLTRANSFERASE/DEACETYLASE ACTIVITY | SIRTRIS PHARMACEUTICALS INC (US) | 2012-02-01 | — | — | EP | disclosed |
| US-20100168084-A1 | Therapeutic compounds and related methods of use | ELIXIR PHARMACEUTICALS, INC. | 2010-07-01 | — | — | US | disclosed |
| US-20100168084-A1 | Therapeutic compounds and related methods of use | ELIXIR PHARMACEUTICALS, INC. | 2010-07-01 | — | — | US | disclosed |
| US-20090221020-A1 | Mass Spectrometry Assays for Acetyltransferase/Deacetylase Activity | SIRTRIS PHARMACEUTICALS, INC (US) | 2009-09-03 | — | — | US | disclosed |
| US-20090221020-A1 | Mass Spectrometry Assays for Acetyltransferase/Deacetylase Activity | SIRTRIS PHARMACEUTICALS, INC (US) | 2009-09-03 | — | — | US | disclosed |
| US-20090069301-A1 | Acridine and Quinoline Derivatives as Sirtuin Modulators | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| US-20090069301-A1 | Acridine and Quinoline Derivatives as Sirtuin Modulators | SIRTRIS PHARMACEUTICALS, INC. (US) | 2009-03-12 | — | — | US | disclosed |
| US-20080293081-A1 | Fluorescence Polarization Assays for Acetyltransferase/Deacetylase Activity | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| US-20080293081-A1 | Fluorescence Polarization Assays for Acetyltransferase/Deacetylase Activity | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| WO-2007064902-A2 | MASS SPECTROMETRY ASSAYS FOR ACETYLTRANSFERASE/DEACETYLASE ACTIVITY | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168084-A1 | Therapeutic compounds and related methods of use | EP300, KAT2A, KAT6B | BCHE 742/4885ACHE 1167/4885APP 3630/4885 |
| US-20090069301-A1 | Acridine and Quinoline Derivatives as Sirtuin Modulators | SIRT1, SIRT3, SIRT2 | BCHE 3399/4885ACHE 331/4885APP 3630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.